Roivant Social Ventures is ranked #115 of 142 philanthropy & grantmaking organizations in New York, NY, with an America's Best Score of 64 out of 100, based on its 2025 Form 990.
Roivant Social Ventures is a 501(c)(3) organization, classified under Philanthropy & Grantmaking (NTEE T30). Contributions are tax-deductible.
1 Pennsylvania Plaza 54Th Fl, New York, NY 10119-5501
Among the 221 scored philanthropy & grantmaking organizations in New York, Roivant Social Ventures holds 16.1 months of operating reserves (peer median 12.3 months), runs a typical yearly deficit of 9.3% (peers: surplus of 4.2%), and has grown spending 29.5% a year (peers: grown spending 6.6% a year).
In fiscal year 2025 it reported $306,829 in revenue and $287,235 in expenses, with contributions making up 99.4% of revenue.
Promote systemic, sustained improvements to the way healthcare is accessed and delivered.
Main program · fiscal year 2023
The organization had the following initiatives for the fiscal-year ending March 31, 2023: (I)launched partnership with the university of North Carolina at chapel hill, eshelman center for innovation, on our initiative to improve diversity in senior leadership in the biopharma industry. The first step in this partnership involved a spring 2023 "making medicines" class, co-taught by rsv president an… Read more
The organization had the following initiatives for the fiscal-year ending March 31, 2023: (I)launched partnership with the university of North Carolina at chapel hill, eshelman center for innovation, on our initiative to improve diversity in senior leadership in the biopharma industry. The first step in this partnership involved a spring 2023 "making medicines" class, co-taught by rsv president and CEO lindsay androski that featured industry leaders as guest speakers. The class was coupled with paid summer internship opportunities for talented students interested in a career in biopharma. (II)launched partnership with vanderbilt university's drug repurposing program, focused on development of existing "shelved" drugs for unmet patient needs. (III)became a founding member of carer (catalyzing access to research and equity in representation), which has developed a "clinical trial diversity scorecard." the scorecard grades biopharma companies that receive new drug approvals from the fda by evaluating how well the company represented the real-world patient population (based on sex, age, ethnicity, and race) in its pivotal clinical trial. In the future, we intend to give awards to the companies that best represent real-world patients in their clinical trials.
$35,997 spent
Where each dollar went · fiscal year 2025
Of every dollar it spent, 57¢ went to programs, 35¢ to management and 8¢ to fundraising.
Programs $163,370
Management $99,855
Fundraising $24,010
In the organization's own words to the IRS, shown for context. None of this affects the America's Best Score, and a Form 990 describes programs without measuring their results.
Spending on programs Not scored; America's Best needs 65%+
57%
Below
Compared with New York peers
Measure
This organization
Peer median
Operating reserves
16.1 mo
12.3 mo
Typical margin
−9.3%
+4.2%
Spending growth
+29.5% / yr
+6.6% / yr
Debt load
5.9%
3.7%
Peers: the 221 New York philanthropy & grantmaking organizations with a score, ranked or below the bar.
Tax filings by year
Financial data extracted from the Form 990 the organization filed with the IRS for each fiscal year. Revenue lines can exceed 100% when other items, such as fundraising event costs, are netted against total revenue.
Revenue$306,829Fiscal year 2025
Expenses$287,235Fiscal year 2025
Total assets$408,573Fiscal year 2025
Total liabilities$24,000Fiscal year 2025
Fiscal year ending March2025
Revenue$306,829
Expenses$287,235
Net income$19,594
Net assets$384,573
Notable sources of revenue
Percent of total revenue
Contributions
$305,032
99.4%
Program services
$0
0.0%
Investment income
$1,797
0.6%
Other (net)
$0
0.0%
Assets / debt
Total assets
$408,573
Total liabilities
$24,000
Net assets
$384,573
Compensation
Not in our extract for this year.
Fiscal year ending March2024
Revenue$123,893
Expenses$254,637
Net income−$130,744
Net assets$368,547
Notable sources of revenue
Percent of total revenue
Contributions
$110,143
88.9%
Program services
$0
0.0%
Investment income
$13,750
11.1%
Other (net)
$0
0.0%
Assets / debt
Total assets
$627,351
Total liabilities
$258,804
Net assets
$368,547
Compensation
Not in our extract for this year.
Fiscal year ending March2023
Revenue$183,093
Expenses$245,560
Net income−$62,467
Net assets$499,291
Notable sources of revenue
Percent of total revenue
Contributions
$170,136
92.9%
Program services
$0
0.0%
Investment income
$12,957
7.1%
Other (net)
$0
0.0%
Assets / debt
Total assets
$755,918
Total liabilities
$256,627
Net assets
$499,291
Compensation
Not in our extract for this year.
Fiscal year ending March2022
Revenue$693,792
Expenses$132,277
Net income$561,515
Net assets$561,758
Notable sources of revenue
Percent of total revenue
Contributions
$684,276
98.6%
Program services
$0
0.0%
Investment income
$9,516
1.4%
Other (net)
$0
0.0%
Assets / debt
Total assets
$838,064
Total liabilities
$276,306
Net assets
$561,758
Compensation
Officers and key employees
$0
Share of expenses
0.0%
About this data
Figures come from IRS Form 990 filings, through the IRS Exempt Organizations Business Master File (2026-11-09) and e-filed returns. Form 990 data typically lags 12–24 months behind an organization's fiscal year. Found an error?